In our previous studies we found that in several analyzed clinically aggressive metastatic colon cancer specimens, as well as in the established colon cancer HCT116 cell line derived from a poorly-differentiated colonic adenocarcinoma, the majority of cells expressed low-to-moderated levels of CD133, CD44 and CD166 [20]. This evidence concerns the gene CD44 and colon adenocarcinoma.